Indication
Synergy for Staphylococcus aureus pneumonia
The phrase "synergy for Staphylococcus aureus pneumonia" does not denote an independent medical diagnosis, clinical condition, or standardized regulatory indication; rather, it reflects a pharmacologic or therapeutic concept where an antimicrobial agent is co-administered to achieve synergistic antibacterial activity against lower respiratory tract infections caused by *Staphylococcus aureus*. Read more about Synergy for Staphylococcus aureus pneumonia
12 drugs 11 manufacturers
Drugs that treat it
Common Synergy for Staphylococcus aureus pneumonia therapies.
GENTAMICIN IN NACL (ISO-OSM) (gentamicin sulfate in sodium chloride, iso-osmotic)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE IN NS (gentamicin sulfate in sodium chloride, iso-osmotic)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThe phrase "synergy for Staphylococcus aureus pneumonia" does not denote an independent medical diagnosis, clinical condition, or standardized regulatory indication; rather, it reflects a pharmacologic or therapeutic concept where an antimicrobial agent is co-administered to achieve synergistic antibacterial activity against lower respiratory tract infections caused by *Staphylococcus aureus*.
*Staphylococcus aureus* pneumonia is an acute, potentially life-threatening infection of the pulmonary parenchyma occurring in both community-acquired and nosocomial settings, frequently affecting vulnerable populations such as mechanically ventilated, post-viral, or immunocompromised individuals.
It is characterized pathophysiologically by intense neutrophil infiltration, bacterial toxin release, and extensive parenchymal destruction, often manifesting clinically as high fevers, severe hypoxemia, purulent sputum production, and radiographic evidence of multifocal consolidations, lung abscesses, or necrotizing cavitation.
- oup.com
The phrase "synergy for Staphylococcus aureus pneumonia" does not denote an independent medical diagnosis, clinical condition, or standardized regulatory indication; rather, it reflects a pharmacologic or therapeutic concept where an antimicrobial agent is co-administered to achieve synergistic antibacterial activity against lower respiratory tract infections caused by *Staphylococcus aureus*
- nih.gov
The phrase "synergy for Staphylococcus aureus pneumonia" does not denote an independent medical diagnosis, clinical condition, or standardized regulatory indication; rather, it reflects a pharmacologic or therapeutic concept where an antimicrobial agent is co-administered to achieve synergistic antibacterial activity against lower respiratory tract infections caused by *Staphylococcus aureus*
- ersnet.org
The phrase "synergy for Staphylococcus aureus pneumonia" does not denote an independent medical diagnosis, clinical condition, or standardized regulatory indication; rather, it reflects a pharmacologic or therapeutic concept where an antimicrobial agent is co-administered to achieve synergistic antibacterial activity against lower respiratory tract infections caused by *Staphylococcus aureus*
- researchgate.net
*Staphylococcus aureus* pneumonia is an acute, potentially life-threatening infection of the pulmonary parenchyma occurring in both community-acquired and nosocomial settings, frequently affecting vulnerable populations such as mechanically ventilated, post-viral, or immunocompromised individuals
- nih.gov
*Staphylococcus aureus* pneumonia is an acute, potentially life-threatening infection of the pulmonary parenchyma occurring in both community-acquired and nosocomial settings, frequently affecting vulnerable populations such as mechanically ventilated, post-viral, or immunocompromised individuals It is characterized pathophysiologically by intense neutrophil infiltration, bacterial toxin release, and extensive parenchymal destruction, often manifesting clinically as high fevers, severe hypoxemia...
- nih.gov
*Staphylococcus aureus* pneumonia is an acute, potentially life-threatening infection of the pulmonary parenchyma occurring in both community-acquired and nosocomial settings, frequently affecting vulnerable populations such as mechanically ventilated, post-viral, or immunocompromised individuals It is characterized pathophysiologically by intense neutrophil infiltration, bacterial toxin release, and extensive parenchymal destruction, often manifesting clinically as high fevers, severe hypoxemia...
- asm.org
It is characterized pathophysiologically by intense neutrophil infiltration, bacterial toxin release, and extensive parenchymal destruction, often manifesting clinically as high fevers, severe hypoxemia, purulent sputum production, and radiographic evidence of multifocal consolidations, lung abscesses, or necrotizing cavitation
Personalize your experience
Follow Synergy for Staphylococcus aureus pneumonia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.